Stock NB3 NEUROCRINE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Neurocrine Biosciences, Inc. Deutsche Boerse AG

Equities

NB3

US64125C1099

Real-time Estimate Tradegate
Other stock markets
 09:40:47 2024-07-11 am EDT 		5-day change 1st Jan Change
135.2 EUR -0.29% Intraday chart for Neurocrine Biosciences, Inc. +5.88% +13.55%
Jul. 09 RBC Cuts Price Target on Neurocrine Biosciences to $136 From $141, Keeps Sector Perform Rating MT
Jul. 03 ANALYST RECOMMENDATIONS : Alphabet, Nike, Nvidia, Tesla, Starbucks... Our Logo

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
RBC Cuts Price Target on Neurocrine Biosciences to $136 From $141, Keeps Sector Perform Rating
MT
ANALYST RECOMMENDATIONS : Alphabet, Nike, Nvidia, Tesla, Starbucks...
Our Logo
Neurocrine Biosciences Insider Sold Shares Worth $1,401,864, According to a Recent SEC Filing
MT
Neurocrine Biosciences Says US FDA Accepts NDAs With Priority Review for Adrenal Gland Disease Drug
MT
Neurocrine Biosciences Gets FDA Priority Review for Crinecerfont
DJ
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
PR
Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
CI
Neurocrine Biosciences, Inc.(NasdaqGS:NBIX) added to Russell 1000 Defensive Index
CI
Neurocrine Biosciences, Inc.(NasdaqGS:NBIX) added to Russell 1000 Growth-Defensive Index
CI
Transcript : Neurocrine Biosciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-13-2024 10:40 AM
Groundbreaking Study by MAIA Biotechnology (NYSE: MAIA) Indicates Promising New Treatment for Advanced Lung Cancer
AQ
Transcript : Neurocrine Biosciences, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 02:30 PM
Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024
PR
Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
CI
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
PR
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
PR
Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
CI
Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing
MT
Neurocrine Biosciences to Participate at Investor Conferences in June
PR
Neurocrine Biosciences to Present New Phase 3 CAHtalyst Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NBIX Stock
  4. NB3 Stock
  5. News Neurocrine Biosciences, Inc.